|
gptkbp:instanceOf
|
antineoplastic agent
platinum-based antineoplastic agent
|
|
gptkbp:approvalYear
|
1989
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
L01XA02
|
|
gptkbp:brand
|
gptkb:Paraplatin
|
|
gptkbp:CASNumber
|
41575-94-4
|
|
gptkbp:chemicalFormula
|
C6H12N2O4Pt
|
|
gptkbp:color
|
white
|
|
gptkbp:contraindication
|
hypersensitivity to platinum compounds
severe myelosuppression
|
|
gptkbp:developedBy
|
gptkb:Johnson_Matthey
|
|
gptkbp:eliminationHalfLife
|
1.5–6 hours
|
|
gptkbp:excretion
|
renal
|
|
gptkbp:firstSynthesized
|
1980s
|
|
gptkbp:form
|
powder
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Carboplatin
|
|
gptkbp:IUPACName
|
gptkb:cis-diammine(cyclobutane-1,1-dicarboxylato)platinum(II)
|
|
gptkbp:KEGGID
|
D00217
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
DNA crosslinking
|
|
gptkbp:MeSH_ID
|
D015313
|
|
gptkbp:metabolism
|
non-enzymatic
|
|
gptkbp:molecularWeight
|
371.25 g/mol
|
|
gptkbp:origin
|
second-generation platinum compound
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:PubChem_CID
|
5311293
4474412
CHEMBL1372
DB00958
|
|
gptkbp:relatedTo
|
gptkb:cisplatin
|
|
gptkbp:routeOfAdministration
|
intravenous
|
|
gptkbp:sideEffect
|
nausea
vomiting
nephrotoxicity
allergic reactions
ototoxicity
myelosuppression
|
|
gptkbp:solubility
|
soluble in water
|
|
gptkbp:storage
|
room temperature
|
|
gptkbp:UNII
|
Q1K0A10YF7
|
|
gptkbp:usedFor
|
gptkb:cancer
testicular cancer
head and neck cancer
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
included
|
|
gptkbp:bfsParent
|
gptkb:Non-Small_Cell_Lung_Cancer
|
|
gptkbp:bfsLayer
|
6
|